Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huashi Runzao Formula is a Traditional Chinese Medicine (TCM) herbal formulation developed by the China-Japan Friendship Hospital for the treatment of primary Sjogren's syndrome (pSS). The formula is designed to address the TCM patterns of 'dampness-heat' (Huashi) and 'dryness' (Runzao), which are central to the pathogenesis of pSS in Chinese medical theory. It is currently being investigated in clinical trials as an adjunctive therapy to standard treatments like hydroxychloroquine, aiming to improve salivary and lacrimal gland function, reduce systemic inflammation, and enhance the quality of life for patients with pSS. As a multi-component botanical product, it likely exerts its effects through immunomodulatory and anti-inflammatory pathways, though its specific molecular targets remain to be fully characterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huashi runzao formula.